Nicolas Gendron on The Emerging Role of CLIA in The Diagnosis Strategy for HIT
Nicolas Gendron, Research Fellow, Hematologist at Boston Children’s Hospital, shared a proud post on LinkedIn:
”New online publication in Blood VTH, Blood Journals Portfolio
Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin treatments.
Its rapid and reliable diagnosis is essential to adapt management and improve the prognosis of patients.
At the HEGP, we compared the diagnostic performance for the detection of anti-PF4/H antibodies of the HemosIL AcuStar HIT-IgG test (CLIA, Werfen ) with that of our Zymutest HIA IgG reference test (ELISA, HYPHEN BioMed ), in 113 patients suspected of TIH (score 4Ts >3), taking as a reference the result of the platelet function test by radiolabeled serotonin release (RAS).
Excellent sensitivity and specificity of both tests
- Very few discordant cases among patients with confirmed HIT
- Overall agreement between the two techniques: 91.2%
- CLIA has proven to be reliable, fast and efficient
These findings support the use of CLIA as a rapid and relevant diagnostic tool in the diagnosis strategy for HIT
Congratulations to Carla Rial and everyone involved in this great collaborative work!
Shaya Sable, Christine Le Beller, Aurélie Sarthou, Mauge Laetitia, Justine Piazza, Roya Nili Maude Laney, Isabelle Presot Jean-Luc Diehl, Agnès Lillo-Le Louet, Anne Godier, David Smadja, Helley-Russick Dominique
Paris Cardiovascular Research Center – PARCC
Université Paris Cité Faculté de Santé – Université Paris Cité
Université Paris Cité Médecine Greater Paris University Hospitals – AP-HP
Werfen Werfen North America”
Read the full article in Blood VTH.
Article: Evaluation of a chemiluminescent immunoassay IgG anti-PF4/H in the Diagnosis of Heparin-Induced Thrombocytopenia
Authors: Carla Rial, Nicolas Gendron, Christine Le Beller, Shaya Sable, Aurélie Sarthou, Laetitia Mauge, Justine Piazza, Roya Nili, Maude Laney, Isabelle Presot, Jean-Luc Diehl, Anne Godier, Agnès Lillo-Le Louet, David M. Smadja, Dominique Helley
Stay updated on the latest scientific advances in the field of platelet disorders with Hemostasis Today.
-
Nov 10, 2025, 10:16Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
-
Nov 10, 2025, 10:15Laurent Bertoletti Invites You to the Joint INNOVTE and GITA Meeting on Hormones and Thrombosis
-
Nov 10, 2025, 10:15Christopher Cannon: DOAC Monotherapy Wins Again
-
Nov 10, 2025, 10:14Marieke Kruip on Sex differences in Outcomes of VKA Treatment in Patients with Mechanical Heart Valve
-
Nov 10, 2025, 10:14Ana Paula Lacombe: From Research to Bedside, Innovation in Stroke Care is Moving Fast!
-
Nov 10, 2025, 10:13Jan Sloves: Understanding Iliofemoral DVT – What You Can’t Afford to Miss
-
Nov 10, 2025, 10:12Mohamed Rawy Shares a Comprehensive Guide For Anticoagulation
-
Nov 10, 2025, 10:10Marc Carrier: Proud to Share the Results of the WAVe Study
-
Nov 10, 2025, 10:07Frederik Denorme – The New PI at the Laboratory of Cell Biology and Histology at University of Antwerp